SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:kth ;hsvcat:3"

Sökning: LAR1:kth > Medicin och hälsovetenskap

  • Resultat 1-10 av 6021
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Falk Erhag, Hanna, et al. (författare)
  • Concluding Remarks
  • 2022
  • Ingår i: A Multidisciplinary Approach to Capability in Age and Ageing. - Chem : Springer. - 9783030780654 ; 18:2, s. 143-144
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
2.
  • Darmanis, Spyros, et al. (författare)
  • Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors
  • 2013
  • Ingår i: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 8:11, s. e81712-
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundPatients with well-differentiated small intestine neuroendocrine tumors (WD-SI-NET) are most often diagnosed at a metastatic stage of disease, which reduces possibilities for a curative treatment. Thus new approaches for earlier detection and improved monitoring of the disease are required.Materials and methodsSuspension bead arrays targeting 124 unique proteins with antibodies from the Human Protein Atlas were used to profile biotinylated serum samples. Discoveries from a cohort of 77 individuals were followed up in a cohort of 132 individuals both including healthy controls as well as patients with untreated primary WD-SI-NETs, lymph node metastases and liver metastases.Results A set of 20 antibodies suggested promising proteins for further verification based on technically verified statistical significance. Proceeding, we assessed the classification performance in an independent cohort of patient serum, achieving, classification accuracy of up to 85% with different subsets of antibodies in respective pairwise group comparisons. The protein profiles of nine targets, namely IGFBP2, IGF1, SHKBP1, ETS1, IL1α, STX2, MAML3, EGR3 and XIAP were verified as significant contributors to tumor classification.ConclusionsWe propose new potential protein biomarker candidates for classifying WD-SI-NET at different stage of disease. Further evaluation of these proteins in larger sample sets and with alternative approaches is needed in order to further improve our understanding of their functional relation to WD-SI-NET and their eventual use in diagnostics.
  •  
3.
  •  
4.
  • Altay, Özlem, et al. (författare)
  • Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
  • 2021
  • Ingår i: Advanced Science. - : Wiley. - 2198-3844. ; 8:17
  • Tidskriftsartikel (refereegranskat)abstract
    • COVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD+) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID-19 patients. CMAs include l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form of l-carnitine. Placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials are conducted to investigate the time of symptom-free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
  •  
5.
  • Huvila, J., et al. (författare)
  • Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma
  • 2018
  • Ingår i: Gynecologic Oncology. - : Academic Press Inc.. - 0090-8258 .- 1095-6859. ; 149:1, s. 173-180
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: In clinical practise, prognostication of endometrial cancer is based on clinicopathological risk factors. The use of immunohistochemistry-based markers as prognostic tools is generally not recommended and a systematic analysis of their utility as a panel is lacking. We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information. Methods: A cohort of 306 EEC specimens was profiled using tissue microarray (TMA). Cost- and time-efficient immunohistochemical analysis of well-established tissue biomarkers (ER, PR, HER2, Ki-67, MLH1 and p53) and two new biomarkers (L1CAM and ASRGL1) was carried out. Statistical modelling with embedded variable selection was applied on the staining results to identify minimal prognostic panels with maximal prognostic accuracy without compromising generalizability. Results: A panel including p53 and ASRGL1 immunohistochemistry was identified as the most accurate predictor of relapse-free and disease-specific survival. Within this panel, patients were allocated into high- (5.9%), intermediate- (29.5%) and low- (64.6%) risk groups where high-risk patients had a 30-fold risk (P < 0.001) of dying of EEC compared to the low-risk group. Conclusions: P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities. 
  •  
6.
  • Uhlén, Mathias, et al. (författare)
  • A pathology atlas of the human cancer transcriptome
  • 2017
  • Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 357:6352, s. 660-
  • Tidskriftsartikel (refereegranskat)abstract
    • Cancer is one of the leading causes of death, and there is great interest in understanding the underlying molecular mechanisms involved in the pathogenesis and progression of individual tumors. We used systems-level approaches to analyze the genome-wide transcriptome of the protein-coding genes of 17 major cancer types with respect to clinical outcome. A general pattern emerged: Shorter patient survival was associated with up-regulation of genes involved in cell growth and with down-regulation of genes involved in cellular differentiation. Using genome-scale metabolic models, we show that cancer patients have widespread metabolic heterogeneity, highlighting the need for precise and personalized medicine for cancer treatment. All data are presented in an interactive open-access database (www.proteinatlas.org/pathology) to allow genome-wide exploration of the impact of individual proteins on clinical outcomes.
  •  
7.
  • Altay, Özlem, et al. (författare)
  • Current Status of COVID-19 Therapies and Drug Repositioning Applications
  • 2020
  • Ingår i: Iscience. - : Elsevier BV. - 2589-0042. ; 23:7
  • Tidskriftsartikel (refereegranskat)abstract
    • The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.
  •  
8.
  • Buist, Mirka, et al. (författare)
  • Novel Wearable Device for Mindful Sensorimotor Training: Integrating Motor Decoding and Somatosensory Stimulation for Neurorehabilitation
  • 2024
  • Ingår i: IEEE Transactions on Neural Systems and Rehabilitation Engineering. - : Institute of Electrical and Electronics Engineers (IEEE). - 1558-0210 .- 1534-4320. ; 32, s. 1515-1523
  • Tidskriftsartikel (refereegranskat)abstract
    • Sensorimotor impairment is a prevalent condition requiring effective rehabilitation strategies. This study introduces a novel wearable device for Mindful Sensorimotor Training (MiSMT) designed for sensory and motor rehabilitation. Our MiSMT device combines motor training using myoelectric pattern recognition along sensory training using two tactile displays. This device offers a comprehensive solution, integrating electromyography and haptic feedback, lacking in existing devices. The device features eight electromyography channels, a rechargeable battery, and wireless Bluetooth or Wi-Fi connectivity for seamless communication with a computer or mobile device. Its flexible material allows for adaptability to various body parts, ensuring ease of use in diverse patients. The two tactile displays, with 16 electromagnetic actuators each, provide touch and vibration sensations up to 250 Hz. In this proof-of-concept study, we show improved two-point discrimination after 5 training sessions in participants with intact limbs (p=0.047). We also demonstrated successful acquisition, processing, and decoding of myoelectric signals in offline and online evaluations. In conclusion, the MiSMT device presents a promising tool for sensorimotor rehabilitation by combining motor execution and sensory training benefits. Further studies are required to assess its effectiveness in individuals with sensorimotor impairments. Integrating mindful sensory and motor training with innovative technology can enhance rehabilitation outcomes and improve the quality of life for those with sensorimotor impairments.
  •  
9.
  • Mebius, Alexander, et al. (författare)
  • Research gaps in the philosophy of evidence-based medicine
  • 2016
  • Ingår i: Philosophy Compass. - : John Wiley & Sons. - 1747-9991. ; 11:11, s. 757-771
  • Tidskriftsartikel (refereegranskat)abstract
    • Increasing philosophical attention is being directed to the rapidly growing discipline of evidence-based medicine (EBM). Philosophical discussions of EBM, however, remain narrowly focused on randomization, mechanisms, and the sociology of EBM. Other aspects of EBM have been all but ignored, including (a) the nature of clinical reasoning and the question of whether it can be standardized; (b) the application of EBM principles to the logic, value, and ethics of diagnosis and prognosis; (c) evidence synthesis (systematic reviews and meta-analyses); and (d) the nature and ethics of placebo controls. Philosophical analysis in each of these areas has the potential to enhance the discussion of EBM methodology and practice. 
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 6021
Typ av publikation
tidskriftsartikel (4539)
konferensbidrag (691)
annan publikation (224)
doktorsavhandling (158)
forskningsöversikt (149)
bokkapitel (104)
visa fler...
rapport (71)
patent (39)
licentiatavhandling (29)
konstnärligt arbete (10)
bok (7)
samlingsverk (redaktörskap) (4)
proceedings (redaktörskap) (3)
recension (2)
visa färre...
Typ av innehåll
refereegranskat (4869)
övrigt vetenskapligt/konstnärligt (1079)
populärvet., debatt m.m. (72)
Författare/redaktör
Uhlén, Mathias (329)
Eiken, Ola (281)
Nilsson, Peter (201)
Tolmachev, Vladimir (139)
Mardinoglu, Adil (133)
Noz, Marilyn E. (133)
visa fler...
Maguire Jr., Gerald ... (127)
Schwenk, Jochen M. (107)
Lundeberg, Joakim (104)
Pontén, Fredrik (88)
Mekjavic, I.B. (88)
Löfblom, John (86)
Gennser, Mikael (86)
Orlova, Anna (80)
Keramidas, Michail E ... (77)
Ståhl, Stefan (68)
Forsman, Mikael, Pro ... (67)
Mardinoglu, Adil, 19 ... (65)
Dellve, Lotta (63)
Eriksson Karlström, ... (57)
Brismar, Hjalmar (55)
Kumar, Arvind (55)
Nielsen, Jens B, 196 ... (54)
Zhang, Cheng (54)
Borén, Jan, 1963 (54)
Mekjavic, Igor B. (53)
Mitran, Bogdan (52)
Turkez, Hasan (50)
Orlova, Anna, 1960- (49)
Zeleznik, Michael P. (49)
Bhattacharya, Prosun ... (48)
Garousi, Javad (48)
Kölegård, Roger (48)
Ekstedt, Mirjam (48)
Jirström, Karin (47)
Grönkvist, Mikael (47)
Danielsson, Mats (46)
Vorobyeva, Anzhelika (46)
Fagerberg, Linn (45)
Önfelt, Björn (45)
Altai, Mohamed (44)
Hober, Sophia, Profe ... (43)
Danielsson, Mats, Pr ... (43)
Eriksson, Andrea, 19 ... (43)
Fransén, Erik, 1962- (42)
Forsman, Mikael (41)
Dellve, Lotta, 1965 (41)
Sundberg, Johan (40)
Lundberg, Emma (40)
Månberg, Anna, 1985- (40)
visa färre...
Lärosäte
Kungliga Tekniska Högskolan (6021)
Karolinska Institutet (1882)
Uppsala universitet (659)
Göteborgs universitet (302)
Stockholms universitet (277)
Lunds universitet (270)
visa fler...
Linköpings universitet (199)
Chalmers tekniska högskola (196)
Umeå universitet (124)
Högskolan i Borås (95)
RISE (89)
Linnéuniversitetet (79)
Högskolan i Gävle (55)
Sveriges Lantbruksuniversitet (52)
Örebro universitet (49)
Högskolan Dalarna (44)
Mälardalens universitet (43)
Gymnastik- och idrottshögskolan (36)
Mittuniversitetet (35)
Malmö universitet (34)
Jönköping University (23)
Marie Cederschiöld högskola (22)
Röda Korsets Högskola (19)
Södertörns högskola (18)
Karlstads universitet (14)
Luleå tekniska universitet (13)
Högskolan i Skövde (13)
Högskolan i Halmstad (8)
Blekinge Tekniska Högskola (6)
VTI - Statens väg- och transportforskningsinstitut (6)
Högskolan Kristianstad (4)
Sophiahemmet Högskola (4)
Försvarshögskolan (3)
IVL Svenska Miljöinstitutet (2)
Högskolan Väst (1)
Handelshögskolan i Stockholm (1)
visa färre...
Språk
Engelska (5876)
Svenska (124)
Tyska (5)
Japanska (4)
Nygrekiska (4)
Danska (2)
visa fler...
Portugisiska (2)
Franska (1)
Ryska (1)
Norska (1)
Estniska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Naturvetenskap (1048)
Teknik (647)
Samhällsvetenskap (201)
Humaniora (60)
Lantbruksvetenskap (35)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy